Our Company
Press Release Archive
-
Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV- Proven efficacy and durability of darunavir combined with the improved renal laboratory and bone mineral density profile of emtricitabine/tenofovir alafenamide as compared to emtricitabine/tenofovir ...
-
Johnson & Johnson Reports 2017 Second-Quarter Results
-
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2017
-
JANSSEN ANNOUNCES U.S. FDA APPROVAL OF TREMFYA™ (GUSELKUMAB) FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS
-
Johnson & Johnson at IAS 2017: Latest Innovations from its Janssen Pharmaceutical Companies Include First In-Human Data for Investigational Preventive HIV-1 Vaccine and Phase 3 Pivotal Trial Results for Darunavir-Based, Single-Tablet RegimenFirst in-human, Phase 1/2a data from APPROACH preventive HIV-1 vaccine clinical trial to be featured in oral presentation and included in official IAS press program. Interim results from the Phase 3 ...
-
U.S. FDA Grants Priority Review of XARELTO® (rivaroxaban) sNDA for a 10 mg Dose to Reduce the Risk of Recurrent Venous Thromboembolism (VTE)
-
DePuy Synthes Announces Acquisition of Sentio, LLC to Enable Innovation in Minimally Invasive Spine SurgeryNerve Localization Technology Will Strengthen Position in Minimally Invasive Surgery Market
-
Johnson & Johnson Releases 2016 Health for Humanity Report
-
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
-
Douglas Wallace, Ph.D., Wins 2017 Dr. Paul Janssen Award for Biomedical ResearchJohnson & Johnson Launches Campaign for Champions of Science